Characterization of Immunogenicity of Tumor Necrosis Factor Inhibitors in Arthritis Patients With Poorer Treatment Response Due to Gender, Obesity and Smoking Status.
Status: Recruiting
Location: See location...
Study Type: Observational
SUMMARY
The aim of the study is to explore whether the influence of gender, tobacco smoking and obesity on treatment response in tumor necrosis factor inhibitors (TNFIs) can be explained by high degree of inflammation, human leucocyte antigen (HLA) type, autoantibodies, TNF and TNFI concentration and presence of ADA.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:
• Patients \> 18 years
• Diagnosed with RA, PsA or AS.
• Starting treatment with infliximab or adalimumab.
• Co- treatment with csDMARD or glucocorticoid is acceptable.
• No new bDMARD is initiated at the time of sampling.
Locations
Other Locations
Denmark
Department of rheumatology
RECRUITING
Aalborg
Contact Information
Primary
Karen B Lauridsen, MD
kabula@rn.dk
0045 097665595
Time Frame
Start Date: 2020-08-01
Estimated Completion Date: 2025-12-30
Participants
Target number of participants: 120
Treatments
Patient with arthritis starting infliximab or adalimumab
Patients with Rheumatoid Artritis, Psoriatic Arthritis, Anchylosing Spondylitis starting treament with infliximab or adalimumab
Related Therapeutic Areas
Sponsors
Leads: Aalborg University Hospital